Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Cancer Res. 2019 Dec 17;80(4):732–746. doi: 10.1158/0008-5472.CAN-19-1771

Figure 4:

Figure 4:

Patients with high expression of HPV16 E5 have decreased HLA expression associated with worse disease-free survival. A, B) mRNA expression analyzed by RNAseq in HNSCC from normal, E245 high, and E67 high patients in Johns Hopkins University (JHU) cohort. (Normal; n = 25, E245 high: n = 26, E67 high: n = 10) (A) Correlation analysis of HPV16 E5 expression and HLA-subtype or TAP expression (n = 36, Spearman’s correlation coefficient) (B) Patients were assigned to 3 groups based on the mRNA expression level of HLA (low, average, and high). Patients with low and high expression of HLA are shown. (Chi-square test and residual analysis) C) Disease-free survival and overall survival of patients in JHU cohort. Patients were assigned to groups based on E5 and HLA expression level.